Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study

IMPORTANCE: Enasidenib mesylate, a mutant isocitrate dehydrogenase 2 (IDH2) protein inhibitor that promotes differentiation of leukemic myeloblasts, was recently approved by the US Food and Drug Administration for use in relapsed/refractory (R/R) mutant IDH2 acute myeloid leukemia (AML). During the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: Fathi, Amir T., DiNardo, Courtney D., Kline, Irina, Kenvin, Laurie, Gupta, Ira, Attar, Eyal C., Stein, Eytan M., de Botton, Stephane
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2018
Soggetti:
Brief Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885269/
https://ncbi.nlm.nih.gov/pubmed/29346478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.4695
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi